25-hydroxyvitamin D

There are 1,197 papers on 25-hydroxyvitamin D in aging research: 356 trials and 642 observational studies in people, 13 in animals, 173 reviews. The newest story, Nov 13, 2026: “Low vitamin D linked to greater frailty in adults”.

Biomarker

1,197 papers study it251 more mention it587 findings

MeSH

39 new papers in 30 daysSee all 1,449 papers on 25-hydroxyvitamin D

At a glance

Lower 25-hydroxyvitamin D is linked with higher mortality and incident frailty in human cohorts; levels are also associated with cognition and functional dependency in hospitalized older adults. Human trials report increased levels with vitamin D supplementation, including a calcifediol trial in vitamin D–deficient frail older adults.

587 findings in 432 papers from 1985 to 2026, 75 of them since April 2026

“the minor allele of a DBP SNP (rs7041) was positively associated with both 25OHD (B = 4.46, p = 1.97E-10)”
Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military TrainingJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2016doi:10.1002/jbmr.3008
  • Human trial356
  • Humans642
  • Animals13
  • In silico4

Interventions

37

Cholecalciferol

upin humans131no changein humans2downin humans1+45% to +98%

132 studies
  1. Cholecalciferol increases 25-hydroxyvitamin D in humans (Adults with prediabetes receiving supplementation plus lifestyle advice) (18.4 ± 4.5 to 27.6 ± 2.8 ng/mL).

    “Serum 25(OH) D rose from 18.4 ± 4.5 to 27.6 ± 2.8 ng/mL ( P < 0.001).”

    Human trialAdults with prediabetes receiving supplementation plus lifestyle adviceserum2000 IU once daily3 monthsn = 45

    Effects of Vitamin D 3 Supplementation on Glycaemic Parameters and Insulin Sensitivity in Pre-diabetic Adults: A Prospective Controlled Interventional Study

    The Nigerian postgraduate medical journal

  2. Cholecalciferol increases 25-hydroxyvitamin D in humans (73.0 vs 99.7 vs 120.4 nmol/L).

    “After 12 months, the concentrations were 73.0 ± 17.8, 99.7 ± 21.1 and 120.4 ± 21.8 nmol/L in the placebo, 1600 IU/day and 3200 IU/day arms, respectively (P < 0.001).”

    Human trial12 monthsn = 550

    The effect of vitamin D₃ supplementation on fracture incidence in an aging population - The Finnish vitamin D trial

    Bone

  3. Cholecalciferol increases 25-hydroxyvitamin D in humans (T-scores -1.5 to -2.5) (38.2 ± 7.5 ng/mL vs 28.5 ± 6.8 ng/mL).

    “Mean serum 25(OH)D levels were substantially higher (p = 0.003) in the liposomal group (38.2 ± 7.5 ng/mL) than those in the control cholecalciferol group (28.5 ± 6.8 ng/mL).”

    Human trialT-scores -1.5 to -2.5liposomal800 IU/day + 1000 mg calcium24 monthsfemalesn = 153

    Vitamin D supplementation and bone health in post-menopausal women: a 24-month randomized controlled intervention with enhanced bioavailability formulations

    European journal of clinical nutrition

  4. Cholecalciferol increases 25-hydroxyvitamin D in humans (vitamin D deficiency).

    “Both groups showed significant increases in serum 25(OH)D levels and reductions in PTH from baseline.”

    Human trialvitamin D deficiencyoral10 weeksn = 50

    Efficacy and safety of oral versus high dose intramuscular vitamin D therapy in elderly patients: A randomized controlled study

    Indian Journal of Orthopaedics Surgery

  5. Cholecalciferol increases 25-hydroxyvitamin D in humans (postmenopausal women with T2DM).

    “Serum 25(OH)D and HDL-c levels increased over time during the follow-up period.”

    Human trialpostmenopausal women with T2DM1000 IU/day for 12 months, followed by 2000 IU/day for another 12 months24 monthsfemalesn = 34

    Long-Term Cholecalciferol Supplementation and Metabolic Parameters in Postmenopausal Women with Type 2 Diabetes Mellitus: A Longitudinal Prospective Study

    Diabetology

  6. Cholecalciferol increases 25-hydroxyvitamin D in vitamin D-deficient hemodialysis patients (89.78 ± 33.43 nmol/L at 6 months).

    “The cholecalciferol supplemented group's 25OHD rose to 89.78 ± 33.43 nmol/L at 6 months”

    Human trialin vitamin D-deficient hemodialysis patients100 000 IU monthly oral6 monthsn = 70

    Cholecalciferol and muscle strength in hemodialysis patients: results from the randomized VITADIAL trial

    Clinical kidney journal

  7. Cholecalciferol increases 25-hydroxyvitamin D in humans.

    “allocation to vitamin D3 resulted in a dose-dependent increase in 25-hydroxy-vitamin D (25(OH)D) levels”

    Human trial2000 IU/d or 4000 IU/dn = 305

    Effects of vitamin D on biochemical markers of osteoporosis: a meta-analysis of randomised trials

    The British journal of nutrition

  8. Cholecalciferol increases 25-hydroxyvitamin D in humans (mild to moderate asthma) (p < 0.001).

    “Serum 25(OH)D increased significantly in Groups A and C (p < 0.001) but remained unchanged in Group B.”

    Human trialmild to moderate asthma12 weeks

    Combined effect of pulmonary rehabilitation and vitamin D supplementation on pulmonary function tests in asthma patients

    The Journal of asthma : official journal of the Association for the Care of Asthma

  9. Cholecalciferol increases 25-hydroxyvitamin D in adult epilepsy patients treated with enzymatic antiseizure medications (10.67 ± 8.16 vs. –1.29 ± 3.96 ng/mL).

    “Vitamin D supplementation yielded a significantly greater increase in serum 25(OH)D (10.67 ± 8.16 vs. –1.29 ± 3.96 ng/mL; p < 0.001)”

    Human trialin adult epilepsy patients treated with enzymatic antiseizure medications2,000 IU/day12 weeks

    Effect of vitamin D supplementation on metabolic syndrome and atherosclerosis biomarkers in epilepsy: a randomized controlled trial

    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina

  10. Cholecalciferol increases 25-hydroxyvitamin D in humans (100 and 120 vs 73 nmol/L).

    “After 12 months, the concentrations were 73, 100, and 120 nmol/L in the placebo, 1600 IU/day, and 3200 IU/day arms, respectively.”

    Human trial12 monthsn = 551

    The Effect of Vitamin D₃ Supplementation on the Risk of Falls in a General Population-The Finnish Vitamin D Trial

    Journal of the American Geriatrics Society

All 148

More on Cholecalciferol

Vitamin D

upin humans34no changein humans1+261% baseline values

34 studies
  1. Vitamin D increases 25-hydroxyvitamin D in humans (P < 0.01).

    “Vitamin D supplementation improved serum 25(OH) D levels ( P < 0.01).”

    Human trial24-monthn = 520

    Prevention of Fracture Risk among Older Long-term Care Residents: A Prospective Study from India

    Preventive Medicine Research & Reviews

  2. Vitamin D increases 25-hydroxyvitamin D in women with PCOS.

    “The serum 25(OH)D concentrations at different time points after vitamin D supplementation were significantly higher than that in control group (P < 0.05).”

    Human trialin women with PCOS2000 IU/day12 weeksfemalesn = 60

    Effects of vitamin D supplementation on metabolic parameters in women with polycystic ovary syndrome: a randomized controlled trial

    Journal of ovarian research

  3. Vitamin D increases 25-hydroxyvitamin D in humans (patients with statin-associated muscle symptoms and vitamin D deficiency) (261% of baseline values).

    “Blood vitamin D levels reached 261% of baseline values.”

    Human trialpatients with statin-associated muscle symptoms and vitamin D deficiency6 months

    Effects of Vitamin D Supplementation in Patients with Statin-Associated Muscle Symptoms and Low Vitamin D Levels

    Metabolic syndrome and related disorders

  4. Vitamin D increases 25-hydroxyvitamin D in humans.

    “At the end of the study period 25(OH)D and 1,25(OH)2D levels increase and, PTH, VDBP levels decrease after vitamin D supplementation, yet, although LTL levels increase in both groups, the increase is more prominent in the placebo group.”

    Human trial8 weeksfemalesn = 102

    Leukocyte telomere length as a compensatory mechanism in vitamin D metabolism

    PloS one

  5. Vitamin D increases 25-hydroxyvitamin D in humans (cigarette smokers with a tobacco use disorder; compared with placebo) (β 2.96; 95% CI 0.91–5.01).

    “serum 25 (OH) vitamin D levels increased in the intervention group (β 2.96; 95% CI, 0.91, 5.01; P = 0.006).”

    Human trialcigarette smokers with a tobacco use disorder; compared with placebosupplements50,000 IU every 2 weeks24 weeksn = 60

    The effect of vitamin D supplementation on tobacco-related disorders in individuals with a tobacco use disorder: a randomized clinical trial

    Journal of addictive diseases

  6. Vitamin D increases 25-hydroxyvitamin D in humans (Compared with control; both groups received 25 g canola oil daily).

    “Serum 25(OH)D increased more in the vitamin D supplement group compared to the controls (P = 0.001).”

    Human trialCompared with control; both groups received 25 g canola oil dailytablet1000 IU daily12 weeks

    Effects of vitamin D-fortified oil intake versus vitamin D supplementation on vitamin D status and bone turnover factors: A double blind randomized clinical trial

    Clinical nutrition ESPEN

  7. Vitamin D increases 25-hydroxyvitamin D in humans (from 13.4 ± 0.8 ng/mL to 29.6 ± 0.9 ng/mL).

    “serum 25-hydroxyvitamin D [25(OH)D] level was 13.4 ± 0.8 ng / mL and it markedly increased to 29.6 ± 0.9 ng / mL after daily 1000-IU vitamin D-fortified milk intake for 6 months”

    Human trialfortified milk1000 IU6 months

    Effects of daily 1,000-IU vitamin D-fortified milk intake on skeletal muscle mass, power, physical function and nutrition status in Japanese

    The journal of medical investigation : JMI

  8. Vitamin D increases 25-hydroxyvitamin D in humans.

    “This revealed a significant difference in serum 25-hydroxyvitamin D levels between the intervention and placebo groups.”

    Human trial12 weeksfemales

    Effect of Vitamin D Supplementation on Muscle Strength, Muscle Function, and Body Composition in Vitamin D-Deficient Middle-Aged Women

    Methods in molecular biology (Clifton, N.J.)

  9. Vitamin D increases 25-hydroxyvitamin D in humans (high risk factors for GDM) ((92. 08±29. 69) nmol/L vs (69. 99±25. 10) nmol/L, P<0. 05).

    “The supplementation of VD in early pregnancy can significantly improve the VD nutrition level of pregnant women”

    Human trialhigh risk factors for GDMserum700 U VD and 100 mg of calciumuntil deliveryfemales

    Effects of vitamin D supplementation in early pregnancy on high-risk groups of gestational diabetes mellitus

    Wei sheng yan jiu = Journal of hygiene research

  10. Vitamin D increases 25-hydroxyvitamin D in type 2 diabetes patients with vitamin D deficiency (p˂10-3).

    “After vitamin D supplementation, mean serum 25(OH)D concentration increased significantly (p˂10-3).”

    Human trialin type 2 diabetes patients with vitamin D deficiencythree months

    Influence of vitamin D supplementation on glycemic control in type 2 diabetics

    La Tunisie medicale

All 38

More on Vitamin D

Ergocalciferol

upin humans6

6 studies
  1. Ergocalciferol increases 25-hydroxyvitamin D in humans.

    “At week 12, the mean 25(OH)D level was 96.7 ± 5.8 ng/mL in the vitamin D group and 23.8 ± 4.1 ng/mL in the control group (mean difference: 72.9; 95% confidence interval [CI]: 70.72 to 75.08; p < 0.001).”

    Human trial12 weeksn = 84

    Effect of vitamin D supplementation on skeletal muscle function and quality of life in patients with chronic intestinal failure: a randomized controlled trial : Clean version

    Journal of translational medicine

  2. Ergocalciferol increases 25-hydroxyvitamin D in humans (chronic intestinal failure and vitamin D deficiency) (96.7 ± 5.8 vs. 23.8 ± 4.1 ng/mL, p < 0.001).

    “serum 25-hydroxyvitamin D levels were significantly higher in the vitamin D group than in the control group (96.7 ± 5.8 vs. 23.8 ± 4.1 ng/mL; p < 0.001).”

    Human trialchronic intestinal failure and vitamin D deficiency600,000 units every two weeks10 weeksn = 84

    Effect of vitamin D supplementation on skeletal muscle function and quality of life in patients with chronic intestinal failure: a randomized controlled trial : Clean version

    Journal of translational medicine

  3. Ergocalciferol increases 25-hydroxyvitamin D in humans.

    “Following 6 months of weekly supplementation with 40,000 IU of vitamin D2, there was a statistically significant increase in the median serum 25(OH)D level.”

    Human trial40,000 IU weekly6 monthsn = 115

    Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease

    Clinical and translational science

  4. Ergocalciferol increases 25-hydroxyvitamin D in humans (from 24.9 to 43.1 ng/mL, p < 0.001).

    “After supplementation, median 25(OH)D increased to 43.1 ng/mL (p < 0.001), with a significant reduction in PTH (p < 0.001).”

    Human trial40,000 IU weekly6 monthsn = 115

    Vitamin D Supplementation Improves Muscle Mass, Physical Function, and Quality of Life in Patients With Degenerative Lumbar Disease

    Clinical and translational science

  5. Ergocalciferol increases 25-hydroxyvitamin D in ESKD patients on dialysis (from 14.5 ± 7.3 to 27.2 ± 13.2 ng/mL, P < .001 and from 15.1 ± 6.4 to 28.8 ± 11.5 ng/mL, P < .001).

    “the average serum 25-hydroxyvitamin D levels in the severity-dependent and fixed-dose groups were significantly elevated”

    Human trialin ESKD patients on dialysis6 monthsn = 76

    A Comparison Between Severity-Dependent Protocol and Fixed-Dose Regimen of Oral Vitamin D Supplementation on Correction of Hypovitaminosis D Among Dialysis Patients

    Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation

  6. Ergocalciferol increases 25-hydroxyvitamin D in humans (early postmenopausal women with vitamin D deficiency) (70% achieved >30 ng/ml; p < 0.05).

    “70% of women in group I achieved a sufficient level of serum 25(OH)D (>30 ng/ml). There were significant differences in changes of serum 25(OH)D levels between the two groups (p < 0.05)”

    Human trialearly postmenopausal women with vitamin D deficiency40 000 IU/week12 weeksfemalesn = 88

    The effect of vitamin D2 supplementation on muscle strength in early postmenopausal women: a randomized, double-blind, placebo-controlled trial

    Climacteric : the journal of the International Menopause Society

  7. Ergocalciferol increases 25-hydroxyvitamin D in humans (from 29.9 to 32.4 ng/ml).

    “significantly increased in the combination group (from 29.9 to 32.4 ng/ml).”

    Human trialserum12 weeksfemalesn = 52

    Effects of sunlight exposure and vitamin D supplementation on vitamin D levels in postmenopausal women in rural Thailand: A randomized controlled trial

    Complementary therapies in medicine

  8. Ergocalciferol increases 25-hydroxyvitamin D in humans (compared with placebo).

    “vitamin D treatment significantly raised the plasma 25-hydroxyvitamin D levels (p less than 0.001)”

    Human trialcompared with placebocapsulesplasma15,000 IU weekly2 yearsfemalesn = 109

    A prospective trial of the effect of vitamin D supplementation on metacarpal bone loss in elderly women

    The American journal of clinical nutrition

More on Ergocalciferol

Calcifediol

upin humans4

4 studies
  1. Calcifediol increases 25-hydroxyvitamin D in humans (post-hip fracture surgery) (38.2 vs. 35.2 ng/mL).

    “After one month, both groups showed increased concentrations (38.2 vs. 35.2 ng/mL; p = 0.50).”

    Human trialpost-hip fracture surgery266 μg daily for 5 days or 266 μg weekly for 5 weeksn = 50

    Efficacy of two calcifediol supplementation regimens in older adults post-hip fracture surgery. A clinical trial

    European geriatric medicine

  2. Calcifediol increases 25-hydroxyvitamin D in humans (hypovitaminosis D).

    “Calcifediol and weekly cholecalciferol induced a greater and faster increase of serum 25(OH)D, compared to monthly or single-dose cholecalciferol administration.”

    Human trialhypovitaminosis Doral6 monthsfemales

    Effects of Different Vitamin D Supplementation Schemes in Post-Menopausal Women: A Monocentric Open-Label Randomized Study

    Nutrients

  3. Calcifediol increases 25-hydroxyvitamin D in humans.

    “Supplementation of 25D3 and D3 were associated with increasing serum levels of 25(OH)D (p < 0.001)”

    Human trial150 mcg weeklyhospital admission to 7 months after dischargen = 67

    Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial

    Nutrients

  4. Calcifediol increases 25-hydroxyvitamin D in humans (vitamin D deficient frail older adults) (87.3 ± 20.6 nmol/L vs 43.8 ± 14.1 nmol/L placebo).

    “Blood 25-hydroxycholecalciferol levels were significantly higher after calcifediol supplementation (87.3 ± 20.6 nmol/L) than after placebo (43.8 ± 14.1 nmol/L).”

    Human trialvitamin D deficient frail older adults10 μg per day6 months

    No effect of 25-hydroxyvitamin D supplementation on the skeletal muscle transcriptome in vitamin D deficient frail older adults

    BMC geriatrics

More on Calcifediol

Vitamin D + calcium

upin humans3

3 studies
  1. Vitamin D + calcium increases 25-hydroxyvitamin D in humans (hypovitaminosis D and secondary hyperparathyroidism).

    “Calcium and 25(OH)D increased significantly in both groups.”

    Human trialhypovitaminosis D and secondary hyperparathyroidism1.0-1.25 g calcium plus 400 IU vitamin D6-12 monthsn = 143

    Calcium and vitamin D supplementation failed to improve bone mineral density in Indo-Asians suffering from hypovitaminosis D and secondary hyperparathyroidism

    Rheumatology international

  2. Vitamin D + calcium increases 25-hydroxyvitamin D in humans (vitamin D insufficiency; compared with placebo).

    “supplementation significantly increased BMD, normalized 25-hydroxyvitamin D”

    Human trialvitamin D insufficiency; compared with placebocalcium (500 mg) and vitamin D (400 IU) twice daily1 yrfemalesn = 192

    Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation

    The Journal of clinical endocrinology and metabolism

  3. Vitamin D + calcium increases 25-hydroxyvitamin D in humans (vitamin D deficiency) (Median increase 22.0 ng/ml vs. 4 ng/ml; P < 0.0001).

    “The median increase in serum 25(OH)D was 22.0 ng/ml in the supplemented group and 4 ng/ml in the placebo group (P < 0.0001)”

    Human trialvitamin D deficiencycalcium as carbonateserum500 mg elemental calcium and 400 IU vitamin D twice daily12 monthsfemales

    Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency

    Joint bone spine

More on Vitamin D + calcium

Cholecalciferol + calcium

upin humans2

2 studies
  1. Cholecalciferol + calcium increases 25-hydroxyvitamin D in humans (asymptomatic hypovitaminosis D and low TBS) (29.1 ± 11.7 to 63.2 ± 22.2 nmol/L at 12-months).

    “Mean serum 25(OH)D (nmol/L) showed a significant rise following supplementation (29.1 ± 11.7 at baseline to 68.8 ± 47.4 and 63.2 ± 22.2 at 6- and 12-months, respectively).”

    Human trialasymptomatic hypovitaminosis D and low TBS1 yearn = 50

    One Year Cholecalciferol and Calcium Supplementation Improve BMD But Not Trabecular Bone Score in Asymptomatic Hypovitaminosis D

    Clinical endocrinology

  2. Cholecalciferol + calcium increases 25-hydroxyvitamin D in all eGFR groups.

    “Both active regimens vs. placebo markedly increased serum 25-hydroxyvitamin D levels from baseline in all eGFR groups”

    Human trialin all eGFR groups1,200 mg calcium and 800 IU vitamin D3 daily2 yearsfemales

    The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease

    Clinical nephrology

More on Cholecalciferol + calcium

Vitamin D + magnesium

upin humans2

2 studies
  1. Vitamin D + magnesium increases 25-hydroxyvitamin D in humans (difference = 5.63; CI, -10.0 to -1.21; P = .001).

    “significant increase in serum 25-hydroxyvitamin D concentrations in the vitamin D and magnesium group compared with the placebo group (difference = 5.63; CI, -10.0 to -1.21; P = .001)”

    Human trial12 weeks

    Combined vitamin D and magnesium supplementation does not influence markers of bone turnover or glycemic control: A randomized controlled clinical trial

    Nutrition research (New York, N.Y.)

  2. Vitamin D + magnesium increases 25-hydroxyvitamin D in humans (compared with vitamin D only) (6.3 ± 8.36 ng/mL).

    “The MagD group experienced the greatest increase in serum 25OHD concentrations (6.3 ± 8.36 ng/mL; P < 0.05).”

    Human trialcompared with vitamin D only360 mg magnesium glycinate + 1000 IU vitamin D3 three times daily12 weeksn = 95

    The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial

    Nutrition (Burbank, Los Angeles County, Calif.)

More on Vitamin D + magnesium

Metformin

upin humans2

2 studies
  1. Metformin increases 25-hydroxyvitamin D in humans (high dose compared with low dose metformin) (significantly higher than control, all P < 0.05).

    “BMD and 25-hydroxyvitamin D were significantly higher in the experimental group than in the control group”

    Human trialhigh dose compared with low dose metforminhigh dose0.5 g four times a day12 wkmalesn = 60

    Effects of different doses of metformin on bone mineral density and bone metabolism in elderly male patients with type 2 diabetes mellitus

    World journal of clinical cases

  2. Metformin increases 25-hydroxyvitamin D in DMT2 patients on metformin alone, during vitamin D3 supplementation (+62.6% at 6 months and +50.6% at 12 months versus baseline).

    “The metformin group showed the highest change in circulating vitamin D levels both at 6 months (62.6%) and 12 months (50.6%) as compared to baseline (p < 0.001).”

    Human trialin DMT2 patients on metformin alone, during vitamin D3 supplementation2000 IU daily vitamin D312 monthsn = 121

    Vitamin D supplementation in patients with diabetes mellitus type 2 on different therapeutic regimens: a one-year prospective study

    Cardiovascular diabetology

More on Metformin

Multivitamin

upin humans2

2 studies
  1. Multivitamin increases 25-hydroxyvitamin D in humans (vitamin D insufficiency) (from 19.4 ± 6.3 ng/ml to 22.2 ± 5.2 ng/ml (p = 0.01)).

    “serum 25(OH)D levels significantly increased from 19.4 ± 6.3 ng/ml at baseline to 22.2 ± 5.2 ng/ml (p = 0.01)”

    Human trialvitamin D insufficiencyoral multivitamin 1 tablet (contained vitamin D2 amount 300 units)300 IU/day4 weeksfemales

    Effect of multivitamin on serum 25-hydroxy vitamin D level in postmenopausal women: A randomized, double-blind, placebo-controlled trial

    Osteoporosis and sarcopenia

  2. Multivitamin increases 25-hydroxyvitamin D in humans (33.4+/-2.6 nmol l(-1), P<0.001).

    “There was a greater increase in the MV vs P group for serum 25(OH)D (mean difference+/-standard error, 33.4+/-2.6 nmol l(-1))”

    Human trialtablet6 months

    Multivitamin supplementation improves nutritional status and bone quality in aged care residents

    European journal of clinical nutrition

More on Multivitamin

Whey protein + vitamin D

upin humans1

1 study
  1. Whey protein + vitamin D increases 25-hydroxyvitamin D in humans (4.6 (2.2, 7.1) ng/ml).

    “the estimated mean (95% confidence interval; (CI)) difference in six-month change attributable to the nutritional intervention, controlling for sex and site, was 4.6 (2.2, 7.1) ng/ml”

    Human trial6 monthsn = 149

    Effect of Structured Physical Activity and Nutritional Supplementation on Physical Function in Mobility-Limited Older Adults: Results from the VIVE2 Randomized Trial

    The journal of nutrition, health & aging

  2. Whey protein + vitamin D increases 25-hydroxyvitamin D in humans (7.4 ng/ml versus 1.3 ng/ml).

    “Serum 25(OH)D increased in supplemented group compared to placebo 7.4 ng/ml versus 1.3 ng/ml respectively”

    Human trial150 kcal, 20 g whey protein, 800 IU vitamin D daily24 weeksn = 149

    Effect of Structured Physical Activity and Nutritional Supplementation on Physical Function in Mobility-Limited Older Adults: Results from the VIVE2 Randomized Trial

    The journal of nutrition, health & aging

More on Whey protein + vitamin D

Caloric restriction

upin humans1

1 study
  1. Caloric restriction increases 25-hydroxyvitamin D in humans.

    “Following weight loss, 25(OH)D increased while Hb decreased among both races.”

    Human trialfemales

    Alterations in Hemoglobin and Serum 25-hydroxyvitamin D are Related Before and After Weight Loss Independent of African Admixture

    International journal of sport nutrition and exercise metabolism

  2. Caloric restriction increases 25-hydroxyvitamin D in overweight premenopausal women (AA, +7.8 ± 13.5 vs. EA, +11.2 ± 16.7 nmol/L).

    “Conversely, 25(OH)D increased (AA, 43.4 ± 14.0 vs. EA 68.2 ± 24.3; p < .01) though the magnitude of change (Δ) was not different”

    Human trialin overweight premenopausal womenvery-low calorie dietfemalesn = 64

    Alterations in Hemoglobin and Serum 25-hydroxyvitamin D are Related Before and After Weight Loss Independent of African Admixture

    International journal of sport nutrition and exercise metabolism

More on Caloric restriction

Purified cytoplasm of pollen + vitamin D + vitamin K2

upin humans1

1 study
  1. Purified cytoplasm of pollen + vitamin D + vitamin K2 increases 25-hydroxyvitamin D in humans.

    “Statistically significant differences were found for 25OHD between T0 and T3 in Group A, showing a +63.0% increase (p = 0.0004) and in the comparison between Group A and Group B at T3 (p = 0.0002), as shown in.”

    Human trialat least three monthsfemalesn = 45

    Beneficial Effects of Purified Cytoplasm of Pollen Associated with Vitamin D and Vitamin K2 on Menopausal Symptoms and Bone Health

    Nutrients

More on Purified cytoplasm of pollen + vitamin D + vitamin K2

Citrulline malate

upin humans1

1 study
  1. Citrulline malate increases 25-hydroxyvitamin D in humans (combined with multicomponent exercise) (+3.82 ± 5.01 ng/mL vs. -0.90 ± 4.71 ng/mL).

    “Serum 25(OH)D increased with CM (+3.82 ± 5.01 ng/mL) and decreased with placebo (-0.90 ± 4.71 ng/mL).”

    Human trialcombined with multicomponent exercise3 g/day6 weeksfemalesn = 20

    Citrulline malate linked to faster chair rises in older women

    Clinical nutrition ESPEN

More on Citrulline malate

Caloric restriction + physical activity

upin humans1

1 study
  1. Caloric restriction + physical activity increases 25-hydroxyvitamin D in humans (2.04 ng/mL, 95% CI: 0.20, 3.88).

    “The treatment effect of ILI (vs DSE) on 25(OH)D was 2.04 ng/mL (95% CI: 0.20, 3.88).”

    Human trial4 years

    Weight loss lifestyle intervention and bone health hormonal markers in type 2 diabetes: analysis from look AHEAD study

    Journal of the Endocrine Society

More on Caloric restriction + physical activity

Intensive lifestyle interventions

upin humans1

1 study
  1. Intensive lifestyle interventions increase 25-hydroxyvitamin D in adults with overweight/obesity and T2D at year 1 (+2.04 ng/mL (95% CI: 0.20, 3.88)).

    “At year 1, 25(OH)D had an ILI-related increase of 2.04 ng/mL (95% CI: 0.20, 3.88)”

    Human trialin adults with overweight/obesity and T2D at year 1year 1n = 123

    Weight loss lifestyle intervention and bone health hormonal markers in type 2 diabetes: analysis from look AHEAD study

    Journal of the Endocrine Society

More on Intensive lifestyle interventions

All 37

Effects

52

Mortality

no changein humans3mediatesin humans1HR 1.09

4 studies
  1. 25-hydroxyvitamin D was not clearly linked with mortality in humans (HR 1.09 per 10-ng/mL increase, 95% CI 0.91–1.30; p = 0.354).

    “Serum 25(OH)D was not significantly associated with mortality or length of stay”

    HumansHospitalized adults with documented delirium; per 10-ng/mL increase in serum 25-hydroxyvitamin DMedian follow-up 30.4 monthsn = 184

    Admission Serum 25-Hydroxyvitamin D and Survival in Older Hospitalized Adults with Delirium: A Retrospective Cohort Study

    Diagnostics (Basel, Switzerland)

  2. 25-hydroxyvitamin D is linked with mortality in humans (Partial mediation of the association between light intensity and mortality).

    “Circulating 25(OH)D partially mediated associations between light intensity and mortality, but not advanced CKM syndrome.”

    HumansPartial mediation of the association between light intensity and mortality

    Associations of objectively measured daytime and nighttime light exposure with the severity of cardiovascular-kidney-metabolic syndrome and all-cause mortality: Evidence from a national cohort and genetic analyses

    Maturitas

  3. 25-hydroxyvitamin D was not clearly linked with mortality in humans (multimorbidity and acute respiratory infection).

    “No associations were seen between serum 25(OH)D and LL-37 levels and disease severity, short-term clinical outcome, or long-term survival.”

    Humansmultimorbidity and acute respiratory infectionserum5-yearn = 289

    The long-term prognostic value of serum 25(OH)D, albumin, and LL-37 levels in acute respiratory diseases among older adults

    BMC geriatrics

  4. 25-hydroxyvitamin D was not clearly linked with mortality in participants with albumin <40 g/L.

    “In the group with a lower albumin level (<40 g/L), the associations failed to reach statistical significance in all participants as well as in women and in men.”

    Humansin participants with albumin <40 g/L

    Serum 25-Hydroxyvitamin D, Albumin, and Mortality Among Chinese Older Adults: A Population-based Longitudinal Study

    The Journal of clinical endocrinology and metabolism

Frailty

no changein humans3

3 studies
  1. 25-hydroxyvitamin D was not clearly linked with frailty in humans.

    “However, no significant association between serum 25(OH)D concentration and frailty was observed in women across any analysis.”

    Humansfemalesn = 6,589

    Low Serum 25-Hydroxyvitamin D as a Risk Factor for Frailty in Community-Dwelling Older Men: A Korean Nationwide Study

    Endocrinology and metabolism (Seoul, Korea)

  2. 25-hydroxyvitamin D was not clearly linked with frailty in humans.

    “In women, serum 25(OH)D levels were not significantly associated with frailty indices, pre-frail, or frail status.”

    Humansfemales

    MON-751 Low Serum 25-Hydroxyvitamin D as a Risk Factor for Frailty in Older Men: A Korean Nationwide Study

    ENDO 2025 abstract

  3. 25-hydroxyvitamin D was not clearly linked with frailty in humans (subjects referred to a geriatric frailty clinic).

    “No significant association was reported between 25(OH)D levels and frailty.”

    Humanssubjects referred to a geriatric frailty clinicn = 321

    Is the 25-Hydroxy-Vitamin D Serum Concentration a Good Marker of Frailty?

    The journal of nutrition, health & aging

Bone mineral density

no changein humans2upin humans1downin humans1

2 studies
  1. 25-hydroxyvitamin D is linked with higher bone mineral density in humans (baseline sunny season S-25OHD<45 nmol/L) (2.5% increase (95% CI,0.5-4.6)).

    “each 20 nmol/L increase in S-25OHD during follow-up was associated with a 2.5% increase in hip BMD (95% CI,0.5-4.6).”

    Humansbaseline sunny season S-25OHD<45 nmol/Ltotal hipeach 20 nmol/L increase in S-25OHD12 yearsfemalesn = 1,802

    Long-Term Change in Vitamin D Status and its Association With Change in Total Hip Bone Mineral Density in Older Women: A Population-Based Cohort Study

    Mayo Clinic proceedings. Innovations, quality & outcomes

  2. 25-hydroxyvitamin D was not clearly linked with bone mineral density in humans (dark season S-25OHD) (No difference).

    “No difference in BMD was observed by dark season S-25OHD.”

    Humansdark season S-25OHDtotal hip12 yearsfemalesn = 1,802

    Long-Term Change in Vitamin D Status and its Association With Change in Total Hip Bone Mineral Density in Older Women: A Population-Based Cohort Study

    Mayo Clinic proceedings. Innovations, quality & outcomes

  3. 25-hydroxyvitamin D is linked with lower bone mineral density in humans (sunny season constant S-25OHD<40 nmol/L vs >70 nmol/L) (10.0% (95% CI,3.8%-16.1%) lower).

    “women with sunny season constant S-25OHD<40 nmol/L displayed 10.0% (95% CI,3.8%-16.1%) lower total hip BMD at follow-up.”

    Humanssunny season constant S-25OHD<40 nmol/L vs >70 nmol/Ltotal hip12 yearsfemalesn = 1,802

    Long-Term Change in Vitamin D Status and its Association With Change in Total Hip Bone Mineral Density in Older Women: A Population-Based Cohort Study

    Mayo Clinic proceedings. Innovations, quality & outcomes

  4. 25-hydroxyvitamin D was not clearly linked with bone mineral density in humans (serum 25-hydroxyvitamin D above 84.8 nmol/L).

    “while levels above this threshold showed no significant correlation (p = 0.3377).”

    Humansserum 25-hydroxyvitamin D above 84.8 nmol/Lmales

    Does higher serum 25-hydroxyvitamin D levels will harm bone mineral density?: a cross-sectional study

    BMC endocrine disorders

Muscle strength

upin humans1no changein humans1

2 studies
  1. 25-hydroxyvitamin D was not clearly linked with muscle strength in humans (heart failure).

    “Association between proximal muscle strength with the 25OHD concentration was not significant.”

    Humansheart failuren = 40

    Serum 25-hydroxyvitamin D concentration is associated with functional capacity in older adults with heart failure

    American heart journal

  2. 25-hydroxyvitamin D improves muscle strength in humans (maintenance of optimal serum levels).

    “maintaining optimal serum levels of 25-hydroxyvitamin D is crucial for optimizing bone tissue mineralization, restoring the strength and proprioception of periarticular skeletal muscles”

    Reviewmaintenance of optimal serum levelsperiarticular skeletal muscle

    Role of Vitamin D in Osteoarticular Health

    Nursing Edição Brasileira

Bone mineral density

mediatesin humans1no changein humans1

2 studies
  1. 25-hydroxyvitamin D is linked with bone mineral density in humans (via 25(OH)D) (indirect effect -0.031, p < 0.05).

    “Mediating effect analysis indicated direct (-0.028) and indirect effect (-0.031) effects of NHHR on BMD via 25(OH)D (p < 0.05).”

    Humansvia 25(OH)D

    Relationship Between the Ratio of Nonhigh-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol and Osteoporosis: The Mediating Role of 25(OH)D and the Moderating Effect of BMI

    Diabetes/metabolism research and reviews

  2. 25-hydroxyvitamin D was not clearly linked with bone mineral density in humans.

    “Associations between 25(OH)D and BMD in women were not statistically significant in this population.”

    Humansbonefemales

    Determinants of circulating 25-hydroxyvitamin D concentration and its association with musculoskeletal health in midlife: Findings from the Hertfordshire Cohort Study

    Metabolism open

More on Bone mineral density

Hospital length of stay

no changein humans1

1 study
  1. 25-hydroxyvitamin D was not clearly linked with hospital length of stay in humans (Hospitalized adults with delirium; per 10-ng/mL increase in serum 25-hydroxyvitamin D) (Adjusted median difference −0.81 days per 10-ng/mL increase, 95% CI −2.18 to 0.56; p = 0.250).

    “Adjusted median length of stay was also not associated with serum 25(OH)D”

    HumansHospitalized adults with delirium; per 10-ng/mL increase in serum 25-hydroxyvitamin Dn = 184

    Admission Serum 25-Hydroxyvitamin D and Survival in Older Hospitalized Adults with Delirium: A Retrospective Cohort Study

    Diagnostics (Basel, Switzerland)

Cancer mortality

no changein humans1

1 study
  1. 25-hydroxyvitamin D was not clearly linked with cancer mortality in humans.

    “no association with cancer incidence or mortality was observed for the 25(OH)D increases achieved in the trials.”

    HumansPopulations weighted to reflect the original VITAL or D-Health baseline 25(OH)D distributions; per 30 or 38 nmol/L higher baseline concentration

    Vitamin D supplementation, cancer incidence and mortality: Randomized trials revisited

    European journal of cancer (Oxford, England : 1990)

Cancer incidence

no changein humans1

1 study
  1. 25-hydroxyvitamin D was not clearly linked with cancer incidence in humans.

    “no association with cancer incidence or mortality was observed for the 25(OH)D increases achieved in the trials.”

    HumansPopulations weighted to reflect the original VITAL or D-Health baseline 25(OH)D distributions; per 30 or 38 nmol/L higher baseline concentration

    Vitamin D supplementation, cancer incidence and mortality: Randomized trials revisited

    European journal of cancer (Oxford, England : 1990)

More on Cancer incidence

Cognitive function

mediatesin humans1

1 study
  1. 25-hydroxyvitamin D is linked with cognitive function in humans (Statistical mediation of the association between oxidative balance score and cognition) (Indirect effect a × b = −0.025).

    “The indirect effect of OBS on cognition through 25(OH)D was significant ( a × b = –0·025).”

    HumansStatistical mediation of the association between oxidative balance score and cognitionn = 1,891

    Oxidative balance and cognitive function in Chinese older adults: the mediating role of plasma 25-hydroxyvitamin D

    The British journal of nutrition

Body mass index

mediatesin humans1

1 study
  1. 25-hydroxyvitamin D is linked with body mass index in humans (7% of the total association with BMI; 9% with WC).

    “For a PTH increase from 10 to 65 pg/mL, 25(OH)D mediated 7% of the total association with BMI and 9% with WC.”

    HumansExploratory statistical decomposition of the association with a PTH increase from 10 to 65 pg/mL; not established as causaln = 4,822

    Parathyroid hormone, vitamin D, and general and abdominal adiposity in bariatric surgery candidates: A cross-sectional analysis of the Tehran Obesity Treatment Study

    Medicine

Bone loss

downin humans1

1 study
  1. 25-hydroxyvitamin D decreases bone loss in humans after one-anastomosis gastric bypass (r = 0.635, p = 0.003).

    “Lower bone loss in the left hip showed a strong correlation with higher 25(OH)D concentrations (r = 0.635, p = 0.003).”

    Human trialafter one-anastomosis gastric bypassleft hip12 months

    Changes in Bone Mineral Density Following Weight Loss Induced by One-Anastomosis Gastric Bypass in Patients with Vitamin D Supplementation

    Obesity surgery

Sleep quality

downin humans1

1 study
  1. 25-hydroxyvitamin D impairs sleep quality in humans (vitamin D supplementation during weight loss).

    “a greater magnitude of change in serum 25(OH)D was associated with an increased need to take medications to sleep (ptrend=0.01) and overall worse sleep quality (ptrend<0.01).”

    Human trialvitamin D supplementation during weight loss12 monthsfemales

    Repletion of vitamin D associated with deterioration of sleep quality among postmenopausal women

    Preventive medicine

All 52

Upstream

17

Obesity

downin humans3

3 studies
  1. Obesity decreases 25-hydroxyvitamin D in humans (17.8 nmol/L lower).

    “Compared with participants with a normal body mass index (<25 kg/m(2)), obese women (≥30 kg/m(2)) had a 25-(OH)D level that was 17.8 nmol/L lower.”

    Human trial

    Dose response to vitamin D supplementation in postmenopausal women: a randomized trial

    Annals of internal medicine

  2. Obesity is linked with lower 25-hydroxyvitamin D in humans (postmenopausal) (17.27 (7.85) vs 24.51 (9.60) ng/mL).

    “Women with obesity showed lower levels of vitamin D (O: 17.27 (7.85) ng/mL, NoO: 24.51 (9.60) ng/mL; p < 0.01)”

    Humanspostmenopausalfemalesn = 250

    Influence of Obesity on Bone Turnover Markers and Fracture Risk in Postmenopausal Women

    Nutrients

  3. Obesity is linked with lower 25-hydroxyvitamin D in humans (-4.0 [-6.3--1.7]).

    “obesity (-4.0 [-6.3--1.7])”

    Humansn = 5,356

    The Prevalence of Vitamin D Deficiency and the Determinants of 25(OH)D Concentration in Older Irish Adults: Data From The Irish Longitudinal Study on Ageing (TILDA)

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on Obesity

Age

no changein humans1downin humans1downin mice1

2 studies
  1. Age was not clearly linked with 25-hydroxyvitamin D in vitamin D deficient subgroup.

    “while women maintained a stable plateau (ρ=−0.081, p = 0.178).”

    Humansin vitamin D deficient subgroupfemales

    Sex-Specific Age-Associated Patterns of Vitamin D Status in Urban Ethiopia: A Cross-Sectional Analysis of the Ethiopian Paradox

    Research SquarePreprint

  2. Age is linked with lower 25-hydroxyvitamin D in vitamin D deficient subgroup (slope: -0.046 ng/mL/year).

    “Within the deficient subgroup, men exhibited a significant inverse relationship with age (slope: −0.046 ng/mL/year; ρ=−0.279, p = 0.0006)”

    Humansin vitamin D deficient subgroupmales

    Sex-Specific Age-Associated Patterns of Vitamin D Status in Urban Ethiopia: A Cross-Sectional Analysis of the Ethiopian Paradox

    Research SquarePreprint

  3. Age decreases 25-hydroxyvitamin D in mice.

    “a significant decline in hepatic CYP2R1 protein (one-way ANOVA for trend, P = 0.007) and 25(OH)D (one-way ANOVA for trend, P = 0.002)”

    Animalsserummales

    Decreased Serum 25-Hydroxyvitamin D in Aging Male Mice Is Associated With Reduced Hepatic Cyp2r1 Abundance

    Endocrinology

Total body fat mass

downin humans1

1 study
  1. Total body fat mass decreases 25-hydroxyvitamin D in humans (baseline cross-sectional association) (p<0.0001).

    “The results showed a significant inverse relation between total body fat mass and serum 25OHD (p<0.0001)”

    Human trialbaseline cross-sectional association

    The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women

    The Journal of steroid biochemistry and molecular biology

  2. Total body fat mass is linked with lower 25-hydroxyvitamin D in humans (r=0.19, p<0.0001).

    “Serum 25-OHD levels were inversely correlated with total body fat (r=0.19; p<0.0001) and with lean mass (r=0.13, p=0.03).”

    Humansone-yearn = 488

    The effect of vitamin D supplementation on serum 25(OH)D in thin and obese women

    The Journal of steroid biochemistry and molecular biology

APOA1

no changein humans1

1 study
  1. APOA1 was not clearly linked with 25-hydroxyvitamin D in humans (non-obese T2DM).

    “No significant genotype–vitamin D association was observed in non-obese T2DM.”

    Humansnon-obese T2DMn = 50

    Association of apolipoprotein A1 (rs 5069) genotyping with 25-hydroxyvitamin D deficiency and insulin resistance as a metabolic and genetic difference in obesity and type 2 diabetes mellitus

    European journal of nutrition

More on APOA1

Type 2 diabetes

downin humans1

1 study
  1. Type 2 diabetes is linked with lower 25-hydroxyvitamin D in humans (β = −8.9 nmol/L; 95% CI: −9.3 to −8.5; p = 3.6 × 10−28).

    “Genetically instrumented analyses showed per SD increase in T2D PRS significantly reduced circulating 25(OH)D levels (β = −8.9 nmol/L; 95% CI: −9.3 to −8.5; p = 3.6 × 10−28).”

    Humans

    Polygenic Scores for Type 2 Diabetes Causally Impact Vitamin D Levels Across Diverse Populations

    Preprints.orgPreprint

More on Type 2 diabetes

Non-HDL-to-HDL cholesterol ratio

downin humans1

1 study
  1. Non-HDL-to-HDL cholesterol ratio is linked with lower 25-hydroxyvitamin D in humans (β = -1.145, p = 0.004).

    “In addition, 25(OH)D significantly decreased with elevated NHHR (β = -1.145, p = 0.004).”

    Humans

    Relationship Between the Ratio of Nonhigh-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol and Osteoporosis: The Mediating Role of 25(OH)D and the Moderating Effect of BMI

    Diabetes/metabolism research and reviews

More on Non-HDL-to-HDL cholesterol ratio

Atopic dermatitis

downin humans1

1 study
  1. Atopic dermatitis is linked with lower 25-hydroxyvitamin D in humans (pediatric atopic dermatitis) (p<0.05).

    “Children with AD had significantly lower serum 25(OH)D (p<0.05)”

    Humanspediatric atopic dermatitis

    The Hidden Pathway: Membrane Vitamin D Receptor Deficiency and T-Cell Senescence in Pediatric Atopic Dermatitis - A Retrospective and Cross-Sectional Investigation

    Journal of asthma and allergy

More on Atopic dermatitis

Male sex

downin humans1

1 study
  1. Male sex is linked with lower 25-hydroxyvitamin D in humans during the year after a hip fracture (15.2 ng/mL vs 23.9 ng/mL, p < 0.001).

    “median 25OHD levels were 15.2 ng/mL (IQR 10.0) in men compared with 23.9 ng/mL (IQR 13.4) in women and remained lower in men at 2, 6, and 12 months (all p < 0.001).”

    Humansduring the year after a hip fracture

    Sex-specific associations of vitamin D and bone biomarkers with bone density and physical function during recovery from hip fracture: the Baltimore Hip Studies

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Parkinson's disease

no changein humans1

1 study
  1. Parkinson's disease was not clearly linked with 25-hydroxyvitamin D in humans (Reverse Mendelian randomization).

    “The reverse MR analysis indicated insufficient evidence of PD causing decreased vitamin D levels (P = 0.776).”

    HumansReverse Mendelian randomization

    No association between genetically predicted vitamin D levels and Parkinson's disease

    PloS one

More on Parkinson's disease

Parathyroid hormone

mediatesin humans1

1 study
  1. Parathyroid hormone is linked with 25-hydroxyvitamin D in humans (50.48% mediated).

    “Estimates of the mediation ratio indicated that increased PTH mediated a 50.48% negative correlation between PM2.5 exposure and circulating 25(OH)D level.”

    HumansMediation of the association between fine particulate matter exposure and circulating 25-hydroxyvitamin Dserumn = 13,194

    Parathyroid hormone mediates the adverse impact of air pollution exposure on serum 25-hydroxyvitamin D: A nationwide cross-sectional study in China

    Environmental research

More on Parathyroid hormone

Polypharmacy

downin humans1

1 study
  1. polypharmacy impairs 25-hydroxyvitamin D in humans.

    “Polypharmacy and low muscle strength weaken the recovery of adequate vitamin D serum levels.”

    Human trialhospital admission to 7 months after dischargen = 67

    Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial

    Nutrients

All 17

Associations

182

Mortality

downin humans8upin humans5mixedin humans1HR 0.58–2.03

14 studies
  1. 25-hydroxyvitamin D is associated with mortality in humans (<5 ng/mL vs >=20 ng/mL) (HR 2.03 (95% CI 1.90-2.18)).

    “Mortality hazard ratios were 2.03 (95% CI 1.90-2.18), 1.34 (1.29-1.39), 1.08 (1.04-1.11), respectively, for <5, 5-10 and 10-15, versus [≥]20 ng/mL.”

    Humans<5 ng/mL vs >=20 ng/mLn = 412,020

    Severe vitamin D deficiency is linked to higher mortality

    medRxivPreprint

  2. 25-hydroxyvitamin D is associated with mortality in humans (CKM syndrome stages 0–3; serum 25-hydroxyvitamin D above versus below 52.20 nmol/L) (2% lower risk; HR 0.98, 95% CI 0.97–0.99).

    “Individuals maintaining 25(OH)D levels above these threshold values exhibited 2% reduced all-cause mortality risk”

    HumansCKM syndrome stages 0–3; serum 25-hydroxyvitamin D above versus below 52.20 nmol/Lserumn = 37,551

    Association of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality among individuals incardiovascular-kidney-metabolic syndrome stages 0-3: a cohort study from the NHANES 2001-2018

    Diabetology & metabolic syndrome

  3. 25-hydroxyvitamin D is linked with a lower risk of mortality in humans (hospitalized patients) (18.59 ± 11.12 ng/mL vs. 15.39 ± 11.45 ng/mL, p<0.001).

    “In a logistic regression analysis, only serum 25(OH)D levels, age > 65 years, and malignancy were significantly associated with in-hospital death.”

    Humanshospitalized patientsserum

    MON-748 Vitamin D Status Upon Hospital Admission to the Internal Medicine Department and Its Relationship With Mortality

    ENDO 2025 abstract

  4. 25-hydroxyvitamin D is linked with a higher risk of mortality in humans (low 25(OH)D profile).

    “However, in a Cox proportional hazard regression model, both low VMR profile and low 25(OH)D profile were risk factors for all-cause mortality.”

    Humanslow 25(OH)D profileup to 9 yearsn = 204

    Investigation of the Vitamin D Metabolite Ratio (VMR) as a Marker of Functional Vitamin D Deficiency: Findings from the SarcoPhAge Cohort

    Nutrients

  5. 25-hydroxyvitamin D is associated with mortality in humans (fourth quartile, before and after PSM).

    “the fourth quartile was associated with reduced other-specific mortality before and after PSM.”

    Humansfourth quartile, before and after PSM

    Association Among Vitamin D Supplementation, Serum 25(OH)D Concentrations, and Mortality Risk: A Prospective Cohort Study Using NHANES 2007-2018 Data

    Therapeutic drug monitoring

  6. 25-hydroxyvitamin D is associated with mortality in humans (Postmenopausal women; multivariate-adjusted analysis) (L-shaped relationship; cut-off 73.89 nmol/L).

    “After multivariate adjustment, higher serum 25(OH)D levels were significantly related with lower all-cause and CVD mortality.”

    HumansPostmenopausal women; multivariate-adjusted analysisfemalesn = 6,812

    Association of serum 25-hydroxyvitamin D levels with all-cause and cause-specific mortality among postmenopausal females: results from NHANES

    Journal of translational medicine

  7. 25-hydroxyvitamin D predicts mortality in geriatric hip fracture patients after PSM (AUC 0.695, P=0.002).

    “the AUC for serum Vitamin D for predicting one-year mortality was 0.656 (P=0.006) and 0.695 (P=0.002), respectively.”

    Humansin geriatric hip fracture patients after PSMserum1 year

    Preoperative Vitamin D Deficiency is Associated with Increased One-Year Mortality in Chinese Geriatric Hip Fracture Patients - A Propensity Score Matching Study

    Clinical interventions in aging

  8. 25-hydroxyvitamin D is associated with mortality in humans (compared with 25(OH)D of ≥30 ng/mL) (HR 1.52, 95% CI 1.24-1.86).

    “Compared with 25(OH)D of ≥30 ng/mL, 25(OH)D < 30 ng/mL was associated with increased mortality (HR 1.52, 95% CI 1.24−1.86, p < 0.001).”

    Humanscompared with 25(OH)D of ≥30 ng/mLserummedian follow-up of 32 monthsn = 952

    Associations of Serum 25(OH)D, PTH, and β-CTX Levels with All-Cause Mortality in Chinese Community-Dwelling Centenarians

    Nutrients

  9. 25-hydroxyvitamin D is linked with a lower risk of mortality in humans (negative dose-response).

    “A negative dose-response relationship was observed between 25(OH)D levels and odds of all-cause mortality.”

    Humans7-yearn = 2,154

    The Impact of Vitamin D and Cognitive Function on All-Cause Mortality Among Older Chinese Adults: A Population-based Longitudinal Study

    Research SquarePreprint

  10. 25-hydroxyvitamin D is linked with a lower risk of mortality in humans.

    “both serum 25(OH)D and albumin concentrations were inversely associated with all-cause mortality (Ps < 0.001)”

    Humansn = 1,834

    Serum 25-Hydroxyvitamin D, Albumin, and Mortality Among Chinese Older Adults: A Population-based Longitudinal Study

    The Journal of clinical endocrinology and metabolism

All 14

Frailty

downin humans5upin humans3OR 0.798–2.45

8 studies
  1. 25-hydroxyvitamin D is associated with frailty in humans (25(OH)D ≤ 50 nmol/L versus > 50 nmol/L across all three cohorts).

    “low 25(OH)D concentrations (≤ 50 nmol/L) were consistently associated with higher FI across all three cohorts.”

    Humans25(OH)D ≤ 50 nmol/L versus > 50 nmol/L across all three cohortsn = 13,164

    Low vitamin D linked to greater frailty in adults

    Food science & nutrition

  2. Frailty is associated with 25-hydroxyvitamin D in humans (coronary artery disease before elective percutaneous coronary intervention) (20.02 ± 7.36 (17.53–22.51) ng/mL vs. 23.91 ± 8.92 (21.02–26.81) ng/mL, р = 0.044).

    “Frailty in patients with CAD was associated with significantly lower serum total vitamin D (25-OH) levels compared to non-frail patients”

    Humanscoronary artery disease before elective percutaneous coronary interventionserumn = 174

    ASSOCIATION BETWEEN FRAILTY AND VITAMIN D LEVELS IN PATIENTS WITH CORONARY ARTERY DISEASE

    Complex Issues of Cardiovascular Diseases

  3. 25-hydroxyvitamin D is associated with frailty in humans (lowest quartile vs. highest quartile) (OR 1.71, 95% CI: 1.18-2.48).

    “Men in the lowest quartile of serum 25(OH)D (≤15.7 ng/mL) had significantly higher risk of frailty (Odd ratio, OR = 1.71, 95% CI: 1.18-2.48)”

    Humanslowest quartile vs. highest quartilemales

    MON-751 Low Serum 25-Hydroxyvitamin D as a Risk Factor for Frailty in Older Men: A Korean Nationwide Study

    ENDO 2025 abstract

  4. 25-hydroxyvitamin D is linked with a lower risk of frailty in humans (HR 0.84, 95% CI 0.76, 0.93).

    “Serum 25(OH)D concentrations were inversely associated with frailty risk (per 1 standard deviation higher: hazard ratio: 0.84; 95% confidence interval: 0.76, 0.93).”

    Humans

    Association of adiposity markers, serum 25-hydroxyvitamin D, and frailty in older adults: A prospective cohort study

    The American journal of clinical nutrition

  5. 25-hydroxyvitamin D is associated with frailty in humans (OR 2.45, 95% CI: 1.38 to 4.35).

    “Participants with the lowest quartile of plasma 25(OH) D were more likely to be frail (odds ratio [OR] 2.45, 95% confidence interval [CI]: 1.38 to 4.35) than those in the highest quartile.”

    Humans3-yearn = 1,074

    Functional dentition is a modifier of the association between vitamin D and the frailty index among Chinese older adults: a population-based longitudinal study

    BMC geriatrics

  6. 25-hydroxyvitamin D is linked with a lower risk of frailty in humans (chronic coronary syndrome) (OR = 0.798, 95% CI 0.670-0.949).

    “25(OH)D (OR = 0.798, 95% CI 0.670-0.949) were independently associated with frailty in the three groups of models.”

    Humanschronic coronary syndrome

    A relationship among the blood serum levels of interleukin-6, albumin, and 25-hydroxyvitamin D and frailty in elderly patients with chronic coronary syndrome

    Aging medicine (Milton (N.S.W))

  7. 25-hydroxyvitamin D is linked with a lower risk of frailty in humans (adjusted for age, body mass index, center, and baseline frailty) (OR 0.84 (0.75, 0.95)).

    “25OHD: 0.84 (0.75, 0.95); -4.4%, (-6.7, -2.0)”

    Humansadjusted for age, body mass index, center, and baseline frailty4.3 yearsmalesn = 2,114

    Nonandrogenic Anabolic Hormones Predict Risk of Frailty: European Male Ageing Study Prospective Data

    The Journal of clinical endocrinology and metabolism

  8. Frailty is associated with 25-hydroxyvitamin D in humans.

    “Albumin and 25-hydroxy vitamin D levels decreased as frailty level increased (p<0.05)”

    Humansn = 335

    Association between serum vitamin B12 level and frailty in older adults

    Northern clinics of Istanbul

Dementia

downin humans4upin humans1OR 0.98

5 studies
  1. 25-hydroxyvitamin D is associated with dementia in humans (hospitalized older adults) (OR 0.980, 95% CI: 0.970-0.990).

    “and documented dementia (OR = 0.980; 95% CI: 0.970-0.990; p < 0.001).”

    Humanshospitalized older adultsn = 1,539

    Serum 25-hydroxyvitamin D and cognitive performance in hospitalized older adults: a cross-sectional study from Central Poland

    Frontiers in nutrition

  2. 25-hydroxyvitamin D is linked with a lower risk of dementia in humans (HR = 0.89; 95% CI: 0.86-0.92).

    “higher 25(OH)D was associated with lower risk (HR = 0.89; 95% CI: 0.86-0.92)”

    Humans≤ 15 yearsn = 162,606

    Metabolic signatures, vitamin D, and red cell distribution width in dementia risk: UK Biobank insights

    GeroScience

  3. 25-hydroxyvitamin D is associated with dementia in humans (Serum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographics) (HR 0.58, 95% CI 0.49–0.69).

    “serum 25(OH)D concentrations were inversely associated with the risk of dementia, MCI, and delirium in a dose-dependent manner after adjusting for demographics”

    HumansSerum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographicsserumn = 443,427

    25-hydroxyvitamin D concentrations and risk of incident dementia, mild cognitive impairment, and delirium in 443,427 UK Biobank participants

    Psychiatry research

  4. Dementia is associated with 25-hydroxyvitamin D in dementia patients.

    “The patients with dementia (AD and MD) showed the lowest vitamin D levels, while MCI patients showed higher levels than the other groups.”

    Humansin dementia patientsn = 509

    Characterization of Vitamin D Status in Older Persons with Cognitive Impairment

    Nutrients

  5. 25-hydroxyvitamin D is associated with dementia in post-acute hip fracture patients.

    “The only baseline characteristic significantly associated with serum 25(OH)D levels was dementia.”

    Humansin post-acute hip fracture patientsn = 493

    Vitamin D levels in post-acute hip fractured patients and their association with rehabilitation outcomes

    Disability and rehabilitation

More on Dementia

Bone mineral density

upin humans3mixedin humans1downin humans1

5 studies
  1. 25-hydroxyvitamin D is associated with bone mineral density in humans (Crohn's disease; vitamin D supplementation; normal versus low serum 25-hydroxyvitamin D) (Bone mineral density increases in 68% with normal serum concentrations versus 18% with low concentrations; P = 0.008).

    “Increases in bone mineral density were especially prevalent among patients who received the supplement and had normal serum levels of 25-hydroxyvitamin D (68%)”

    Human trialCrohn's disease; vitamin D supplementation; normal versus low serum 25-hydroxyvitamin Ddistal nondominant forearm1000 IU/day vitamin D1 year

    Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation

    European journal of gastroenterology & hepatology

  2. 25-hydroxyvitamin D predicts bone mineral density in humans (Transgender adults prior to gender-affirming hormone therapy).

    “BMI and 25-OH vitamin D levels were independent predictors of BMD and Z-scores in AMAB individuals.”

    HumansTransgender adults prior to gender-affirming hormone therapyboneassigned male at birthsn = 96

    Impact of reference gender on bone mineral density and fracture risk assessment in transgender adults

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

  3. 25-hydroxyvitamin D is associated with bone mineral density in humans (p = 0.001).

    “Serum concentrations of 25(OH)D were significantly and positively associated with BMD total hip (p = 0.001)”

    Humansn = 212

    Serum 25 hydroxyvitamin D concentrations in individuals over 80 years old and their correlations with musculoskeletal and health parameters

    Endocrine

  4. 25-hydroxyvitamin D predicts bone mineral density in humans.

    “higher 25(OH)D with less loss of tibial trabecular vBMD and CSA in women.”

    Humanstibia1.7 yearsfemales

    Longitudinal Change in Bone Density, Geometry, and Estimated Bone Strength in Older Men and Women From The Gambia: Findings From the Gambian Bone and Muscle Aging Study (GamBAS)

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

  5. 25-hydroxyvitamin D is associated with bone mineral density in humans (p = 0.01).

    “Higher femoral neck BMD was observed in men with higher baseline vitamin D status, after adjustment for age, season, BMI, smoker status, alcohol consumption, physical activity and social class (p = 0.01).”

    Humansadjusted for age, season, BMI, smoker status, alcohol consumption, physical activity and social classbonemales

    Determinants of circulating 25-hydroxyvitamin D concentration and its association with musculoskeletal health in midlife: Findings from the Hertfordshire Cohort Study

    Metabolism open

More on Bone mineral density

Sarcopenia

downin humans4

4 studies
  1. 25-hydroxyvitamin D is associated with sarcopenia in humans (r = -0.48, p < 0.001).

    “Serum 25(OH)D levels were moderately and inversely correlated with sarcopenia-related risk severity (r = -0.48, p < 0.001).”

    Humansn = 148

    Vitamin D Deficiency Is Associated with Greater Sarcopenia-Related Risk Severity and Functional Decline in Older Adults: A Retrospective Cross-Sectional Study

    Medicina (Kaunas, Lithuania)

  2. 25-hydroxyvitamin D predicts sarcopenia in humans (psoriatic arthritis) (P < 0.001).

    “with multivariate analysis, 25(OH)D remained a single significant independent predictor for sarcopenia development in PsA patients ( P < 0.001).”

    Humanspsoriatic arthritisn = 43

    The association between vitamin D serum level and the development of sarcopenia in psoriatic arthritis patients

    Egyptian Rheumatology and Rehabilitation

  3. Sarcopenia is associated with 25-hydroxyvitamin D in humans (psoriatic arthritis) (10.1 vs 33.1 ng/ml, P < 0.001).

    “Serum 25(OH)D levels were statistically significantly less in sarcopenic compared to non-sarcopenic PsA patients (10.1 and 33.1 ng/ml, P < 0.001).”

    Humanspsoriatic arthritisn = 43

    The association between vitamin D serum level and the development of sarcopenia in psoriatic arthritis patients

    Egyptian Rheumatology and Rehabilitation

  4. 25-hydroxyvitamin D is associated with sarcopenia in humans (type 2 diabetes mellitus).

    “Age, lower BMI, reduced serum 25(OH)D, and reduced dietary protein and vitamin D intake were significantly associated with sarcopenia.”

    Humanstype 2 diabetes mellitusn = 110

    Association of Possible Sarcopenia or Sarcopenia with Body Composition, Nutritional Intakes, Serum Vitamin D Levels, and Physical Activity among Patients with Type 2 Diabetes Mellitus in Taiwan

    Nutrients

  5. 25-hydroxyvitamin D is associated with sarcopenia in humans (sarcopenic participants compared with controls, random-effects meta-analysis) (SMD 1.163 (95% CI 0.514, 1.812); I2=99.652%).

    “Sarcopenic participants had significantly lower serum levels of 25(OH)D (SD =1.163; 95% CI 0.514, 1.812; p<0.001; I2=99.652%)”

    Humanssarcopenic participants compared with controls, random-effects meta-analysisn = 19,528

    Does vitamin D affect sarcopenia with insulin resistance in aging?

    Asia Pacific journal of clinical nutrition

More on Sarcopenia

Osteoporosis

downin humans2upin humans2OR 0.924

4 studies
  1. 25-hydroxyvitamin D is linked with a lower risk of osteoporosis in humans (per 1 unit increase in 25(OH)D) (OR = 0.924, p < 0.001).

    “a 7.6% risk reduction per 1 unit increase in 25(OH)D (OR = 0.924, p < 0.001).”

    Humansper 1 unit increase in 25(OH)D

    Relationship Between the Ratio of Nonhigh-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol and Osteoporosis: The Mediating Role of 25(OH)D and the Moderating Effect of BMI

    Diabetes/metabolism research and reviews

  2. 25-hydroxyvitamin D predicts osteoporosis in humans (Low mean 25-hydroxyvitamin D; systemic lupus erythematosus; multivariate analysis).

    “In the multivariate analysis for osteoporosis, older age, lower BMI, low mean 25(OH)D levels, and prednisone dose >5 mg/day remained predictors.”

    HumansLow mean 25-hydroxyvitamin D; systemic lupus erythematosus; multivariate analysisn = 1,003

    Role of Prednisone and 25-Hydroxyvitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus

    Arthritis care & research

  3. 25-hydroxyvitamin D is associated with osteoporosis in humans (p = 0.001).

    “In multiple linear regression analysis, age and osteoporosis diagnosis remained negatively associated with 25(OH)D levels (p = 0.021 and p = 0.001, respectively)”

    Humansn = 212

    Serum 25 hydroxyvitamin D concentrations in individuals over 80 years old and their correlations with musculoskeletal and health parameters

    Endocrine

  4. Osteoporosis is associated with 25-hydroxyvitamin D in humans (P = 0.020).

    “Significant positive associations were seen between 25(OH) D levels and osteoporosis (P = 0.020)”

    Humansn = 600

    The Prevalence of Vitamin D and Calcium Supplement use and Association with Serum 25-Hydroxy-vitamin D (25(OH)D) and Demographic and Socioeconomic Variables in Iranian Elderly

    International journal of preventive medicine

More on Osteoporosis

Bone mineral density

upin humans4

4 studies
  1. 25-hydroxyvitamin D is associated with bone mineral density in humans (baseline, before supplementation).

    “Baseline total and free 25(OH)D concentrations were positively associated with 1,25(OH)2D, 24,25(OH)2D (p < 0.001), vitamin D binding protein (DBP) (p < 0.05), BMD, and BMC (p < 0.05).”

    Human trialbaseline, before supplementationbonen = 379

    Vitamin D Supplementation for 12 Months in Older Adults Alters Regulators of Bone Metabolism but Does Not Change Wnt Signaling Pathway Markers

    JBMR plus

  2. 25-hydroxyvitamin D is associated with bone mineral density in humans (serum 25-hydroxyvitamin D below 84.8 nmol/L).

    “In males, a significant positive association was identified for 25(OH)D levels below 84.8 nmol/L (p < 0.0001)”

    Humansserum 25-hydroxyvitamin D below 84.8 nmol/Lmales

    Does higher serum 25-hydroxyvitamin D levels will harm bone mineral density?: a cross-sectional study

    BMC endocrine disorders

  3. 25-hydroxyvitamin D is associated with bone mineral density in humans.

    “positively correlated with serum 25-hydroxyvitamin D levels”

    Humansn = 94

    Risk factors of osteoporosis in elderly inpatients: A cross-sectional single-centre study

    Frontiers in aging

  4. 25-hydroxyvitamin D is associated with bone mineral density in humans.

    “The BMD of the lumbar spine was negatively correlated with female sex and positively correlated with serum 25-hydroxyvitamin D levels”

    Humanslumbar spine

    Association of age, sex, nutritional risk, serum 25-hydroxyvitamin D, serum uric acid, and exercise capacity with bone mineral density in elderly and very elderly inpatients: a cross-sectional study

    Research SquarePreprint

Body mass index

downin humans3

3 studies
  1. 25-hydroxyvitamin D is associated with body mass index in humans (25(OH)D > 35 ng/mL compared with < 12 ng/mL; bariatric surgery candidates) (1.81 kg/m2 lower BMI; 3.30 cm lower WC).

    “Compared with 25(OH)D < 12 ng/mL, concentrations > 35 ng/mL were associated with 1.81 kg/m2 lower BMI”

    Humans25(OH)D > 35 ng/mL compared with < 12 ng/mL; bariatric surgery candidatesn = 4,822

    Parathyroid hormone, vitamin D, and general and abdominal adiposity in bariatric surgery candidates: A cross-sectional analysis of the Tehran Obesity Treatment Study

    Medicine

  2. 25-hydroxyvitamin D is associated with body mass index in humans (β = –1.02 (95% CI –1.46 to –0.58) and β = –1.29 (95% CI –1.77 to –0.80), respectively; both p < 0.0001).

    “Higher baseline vitamin D levels are independently associated with enhanced glycemic and weight loss responses to semaglutide in individuals with T2D.”

    HumansType 2 diabetes treated with semaglutide; baseline 25(OH)D 15–24.9 or ≥25 ng/mL versus <15 ng/mL12 monthsn = 5,300

    Efficacy of Semaglutide in glycemic control, weight loss, and improving lipid profile- the role of baseline vitamin D levels.

    ESC Congress 2026 abstract

  3. 25-hydroxyvitamin D is associated with body mass index in humans (aquatic training group) (r = -0.15; p = 0.04).

    “also between 25(OH)D and BMI for AT and MF groups respectively (r= -0,15; p=0,04/ r= - 0,19; p=0,036).”

    Humansaquatic training groupfemalesn = 180

    Relation among 25(OH)D, Aquatic Exercises, and Multifunctional Fitness on Functional Performance of Elderly Women from the Community

    The journal of nutrition, health & aging

Type 2 diabetes

downin humans2upin humans1OR 0.96

3 studies
  1. 25-hydroxyvitamin D is associated with type 2 diabetes in humans (seasonally normalized 25(OH)D deficiency).

    “Associations previously observed in LHS and TriNetX were reproduced, notably for diabetes, myocardial infarction, cerebrovascular disease, dementia, diabetic retinopathy, and end-stage renal disease”

    Humansseasonally normalized 25(OH)D deficiencyn = 412,020

    Severe vitamin D deficiency is linked to higher mortality

    medRxivPreprint

  2. 25-hydroxyvitamin D is associated with type 2 diabetes in humans (OR = 0.96; 95% CI: 0.94-0.98).

    “Each 1-ng/mL increase in 25(OH)D was associated with lower odds of T2DM (OR = 0.96; 95% CI: 0.94-0.98).”

    Humans1 ng/mL increasen = 946

    Association between vitamin D deficiency and type 2 diabetes in an Indigenous Brazilian population

    Archives of endocrinology and metabolism

  3. 25-hydroxyvitamin D is associated with type 2 diabetes in humans (prospective analysis in white women) (HR = 0.73; 95% CI: 0.62-0.86).

    “Prospectively, lower 25(OH)D was associated with lower diabetes incidence [hazard ratio (HR) = 0.73; 95% CI: 0.62-0.86] in white women.”

    Humansprospective analysis in white women11 yearsfemalesn = 3,000

    Combined associations of 25-hydroxivitamin D and parathyroid hormone with diabetes risk and associated comorbidities among U.S. white and black women

    Nutrition & diabetes

More on Type 2 diabetes

Mild cognitive impairment

downin humans3HR 0.55

3 studies
  1. 25-hydroxyvitamin D is linked with a lower risk of mild cognitive impairment in humans.

    “Higher serum 25-OH-D levels were significantly associated with lower odds of MCI, as well as with MCI across all subgroups (p<0.05).”

    Humansserumn = 866

    Association between serum 25-hydroxyvitamin D levels and cognitive function among older adults in Tianjin, China: a cross-sectional community-based study

    BMJ open

  2. 25-hydroxyvitamin D is associated with mild cognitive impairment in humans (Serum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographics) (HR 0.55, 95% CI 0.37–0.84).

    “serum 25(OH)D concentrations were inversely associated with the risk of dementia, MCI, and delirium in a dose-dependent manner after adjusting for demographics”

    HumansSerum 25-hydroxyvitamin D >64.4 versus <32.4 nmol/L; adjusted for demographicsserumn = 443,427

    25-hydroxyvitamin D concentrations and risk of incident dementia, mild cognitive impairment, and delirium in 443,427 UK Biobank participants

    Psychiatry research

  3. Mild cognitive impairment is associated with 25-hydroxyvitamin D in humans (Compared with cognitively normal controls).

    “the levels were significantly lower in the MCI group than the control group (P = 0.002)”

    HumansCompared with cognitively normal controlsplasman = 228

    Vitamin D status and its association with gradual decline in cognitive function

    Turkish journal of medical sciences

More on Mild cognitive impairment

GC

upin humans2mixedin humans1

3 studies
  1. GC is associated with 25-hydroxyvitamin D in humans (treatment with low dose vitamin D (2000 IU)).

    “We found that rs7041 (located on chromosome 4, GC) was significantly associated with response to vitamin D treatment with low dose vitamin D (2000 IU) at 6 and 12 months (permuted p values 0.001 and 0.023 respectively).”

    Human trialtreatment with low dose vitamin D (2000 IU)one year

    Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial

    EBioMedicine

  2. GC is associated with 25-hydroxyvitamin D in humans (at baseline) (B = 4.46, p = 1.97E-10).

    “the minor allele of a DBP SNP (rs7041) was positively associated with both 25OHD (B = 4.46, p = 1.97E-10)”

    Human trialat baselinen = 748

    Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

  3. GC is associated with 25-hydroxyvitamin D in humans.

    “significant differences in 25(OH)D levels observed between genotypes of the GC gene (rs4588, p = 0.039; rs2282679, p = 0.036).”

    Humansn = 138

    Exploring the impact of vitamin D-related genetic variants on muscular fitness changes in middle-aged and older adults in Kosovo

    Frontiers in public health

More on GC

HbA1c

downin humans2

2 studies
  1. 25-hydroxyvitamin D is associated with HbA1c in humans (healthy overweight or obese) (r = -0.271; P = 0.018).

    “There was a significant correlation between HbA(1c) and 25-hydroxyvitamin D concentrations (r = -0.271; P = 0.018).”

    Human trialhealthy overweight or obesefemalesn = 77

    Does vitamin D3 supplementation improve glucose homeostasis in overweight or obese women? A double-blind, randomized, placebo-controlled clinical trial

    Diabetic medicine : a journal of the British Diabetic Association

  2. 25-hydroxyvitamin D is associated with HbA1c in humans (β = –0.083 (95% CI –0.154 to –0.013), p = 0.020; β = –0.096 (reported 95% CI –0.017 to –0.017), p = 0.016, respectively).

    “Higher baseline vitamin D levels are independently associated with enhanced glycemic and weight loss responses to semaglutide in individuals with T2D.”

    HumansType 2 diabetes treated with semaglutide; baseline 25(OH)D 15–24.9 or ≥25 ng/mL versus <15 ng/mL12 monthsn = 5,300

    Efficacy of Semaglutide in glycemic control, weight loss, and improving lipid profile- the role of baseline vitamin D levels.

    ESC Congress 2026 abstract

More on HbA1c

Body fat mass

downin humans2

2 studies
  1. 25-hydroxyvitamin D is associated with body fat mass in humans (healthy overweight and obese) (r = -0.319, P = 0.005).

    “A significant reverse correlation between changes in serum 25(OH) D concentrations and body fat mass was observed (r = -0.319, P = 0.005).”

    Human trialhealthy overweight and obese12 weeksfemalesn = 77

    A 12-week double-blind randomized clinical trial of vitamin D₃ supplementation on body fat mass in healthy overweight and obese women

    Nutrition journal

  2. 25-hydroxyvitamin D is associated with body fat mass in humans.

    “The serum 25(OH)D level showed a significant negative correlation with body fat mass.”

    Humansn = 163

    Usefulness of Vitamin D Deficiency Questionnaire for Japanese (VDDQ-J) for Screening of Vitamin D Deficiency and Low Muscle Mass in Relatively Healthy Japanese Anti-Aging Health Checkup Examinees

    Journal of nutritional science and vitaminology

Osteocalcin

downin humans1mixedin humans1

2 studies
  1. 25-hydroxyvitamin D is associated with osteocalcin in humans (change in osteocalcin modeled with change in insulin) (model R2 = 25.6%).

    “The change in OC was explained by changes in serum 25OHD and insulin (model R(2) = 25.6%).”

    Human trialchange in osteocalcin modeled with change in insulin6 weeksfemales

    Vitamin D supplementation during short-term caloric restriction in healthy overweight/obese older women: Effect on glycemic indices and serum osteocalcin levels

    Molecular and cellular endocrinology

  2. 25-hydroxyvitamin D is associated with osteocalcin in humans (adjusted for covariates) (β = −0.395, p = 0.001).

    “a significant negative association was observed between 25-OHD concentration and the BTMs; osteocalcin (β = −0.395; p = 0.001)”

    Humansadjusted for covariatesserumn = 69

    Vitamin D and Bone Health of Older Adults within Care Homes: An Observational Study

    Nutrients

More on Osteocalcin

VDR

downin humans1mixedin humans1

2 studies
  1. VDR is associated with 25-hydroxyvitamin D in humans (baseline) (21 ± 10 ng/ml, p = 0.038).

    “The Bat haplotype was associated with lower baseline levels of vitamin D”

    Human trialbaselinefemalesn = 151

    Association Between Bat Vitamin D Receptor 3' Haplotypes and Vitamin D Levels at Baseline and a Lower Response After Increased Vitamin D Supplementation and Exposure to Sunlight

    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition

  2. VDR is associated with 25-hydroxyvitamin D in humans (Chinese women; Cdx-2 promoter polymorphism).

    “In women, the association of Cdx-2 polymorphism with serum 25(OH)D levels was significant”

    HumansChinese women; Cdx-2 promoter polymorphismserumfemalesn = 428

    Cdx-2 polymorphism in Vitamin D Receptor gene was associated with serum 25-hydroxyvitamin D levels, bone mineral density and fracture in middle-aged and elderly Chinese women

    Molecular and cellular endocrinology

More on VDR

All 182

Funding

2 grants since 2017

Japan Society for the Promotion of Science¥7.3M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Lower 25-hydroxyvitamin D is linked with higher mortality in human cohorts; higher levels are associated with lower odds of dementia in hospitalized older adults and lower fragility fracture risk in patients undergoing maintenance hemodialysis. Human trials report that cholecalciferol raises its levels; calcifediol does so in vitamin D–deficient frail older adults.

  2. Summary rewritten as its findings changed.

    As it read before

    Human observational studies link lower 25-hydroxyvitamin D with higher mortality, and higher levels with lower dementia odds in hospitalized older adults and lower fragility-fracture risk in people receiving maintenance hemodialysis. Human trials report increased levels with cholecalciferol; a calcifediol trial also reports increases in vitamin D-deficient frail older adults.

  3. Summary rewritten as its findings changed.

    As it read before

    Lower 25-hydroxyvitamin D is associated with higher mortality and, in men, frailty in human observational studies. Bone associations differ: higher levels accompany higher hip bone density T-scores in men but lower femur T-scores in heart transplant recipients. Human trials report that cholecalciferol and ergocalciferol raise levels.

  4. Summary rewritten as its findings changed.

    As it read before

    A human trial shows cholecalciferol increases 25-hydroxyvitamin D. Human studies associate this biomarker with lower cancer mortality, cardiometabolic risk clustering and physical function after osteoporotic fragility fractures, while one study finds no association with colorectal neoplasms in Lynch syndrome carriers.

  5. Summary written from the findings.

Latest

Dec 2025: 16Jan 2026: 39Feb 2026: 39Mar 2026: 38Apr 2026: 16May 2026: 20Jun 2026: 23Jul 2026: 26Aug 2026: 22Sep 2026: 23Oct 2026: 29Nov 2026: 22313 papers in 12 months
Food Science & Nutrition

Low vitamin D linked to greater frailty in adults

Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.

Cohort studyPopulations

See all 1,449 papers on 25-hydroxyvitamin D